-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Jiacosi Pharmaceuticals (1167.
JAB-21822 is a KRAS G12C inhibitor independently developed by JIAX USING ALLOPHO INHIBITOR technology, which is used for the first-line treatment
About 40,000 new tumor patients with KRAS G12C mutations are added to China every year, and STK11 is a parallel biomarker
Dr.
JIACOS's KRAS G12C inhibitor JAB-21822 is the potential best of its kind for KRAS G12C inhibitors
At present, JAB-21822 is conducting simultaneous single-drug and combination clinical studies